{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T18:08:01Z","timestamp":1778350081465,"version":"3.51.4"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Antidiabetic medications are commonly used around the world, but their safety is still unclear. The aim of this study was to investigate whether long-term use of insulin and oral antidiabetic medications is associated with cancer risk.<\/jats:p>\n            <jats:p>We conducted a well-designed case\u2013control study using 12 years of data from Taiwan's National Health Insurance Research Database and investigated the association between antidiabetic medication use and cancer risk over 20 years. We identified 42,500 patients diagnosed with cancer and calculated each patient's exposure to antidiabetic drugs during the study period. We matched cancer and noncancer subjects matched 1:6 by age, gender, and index date, and used Cox proportional hazard regression and conditional logistic regression, adjusted for potential confounding factors, that is, medications and comorbid diseases that could influence cancer risk during study period.<\/jats:p>\n            <jats:p>Pioglitazone (adjusted odds ratio [AOR], 1.20; 95% confidence interval [CI], 1.05\u20131.38); and insulin and its analogs for injection, intermediate or long acting combined with fast acting (AOR, 1.22; 95% CI, 1.05\u20131.43) were significantly associated with a higher cancer risk. However, metformin (AOR, 1.00; 95% CI, 0.93\u20131.07), glibenclamide (AOR, 0.98; 95% CI, 0.92\u20131.05), acarbose (AOR, 1.06; 95% CI, 0.96\u20131.16), and others do not show evidence of association with cancer risk. Moreover, the risk for specific cancers among antidiabetic users as compared with nonantidiabetic medication users was significantly increased for pancreas cancer (by 45%), liver cancer (by 32%), and lung cancer (by 18%).<\/jats:p>\n            <jats:p>Antidiabetic drugs do not seem to be associated with an increased cancer risk incidence except for pioglitazone, insulin and its analogs for injection, intermediate or long acting combined with fast acting.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000017461","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T15:13:51Z","timestamp":1570029231000},"page":"e17461","source":"Crossref","is-referenced-by-count":24,"title":["Does long-term use of antidiabetic drugs changes cancer risk?"],"prefix":"10.1097","volume":"98","author":[{"given":"Yi-Chun","family":"Liu","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Yuan's General Hospital, Kaohsiung City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phung-Anh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayesha","family":"Humayun","sequence":"additional","affiliation":[{"name":"Department of Public Health and Community Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Shaikh Zayed Medical Complex, Lahore, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo-Chen","family":"Chien","sequence":"additional","affiliation":[{"name":"Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan"},{"name":"International Center for Health Information Technology (ICHIT)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsuan-Chia","family":"Yang","sequence":"additional","affiliation":[{"name":"Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan"},{"name":"International Center for Health Information Technology (ICHIT)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahma Novita","family":"Asdary","sequence":"additional","affiliation":[{"name":"Masters Program in Global Health & Department, College of Public Health, Taipei Medical University, Taipei"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabbir","family":"Syed-Abdul","sequence":"additional","affiliation":[{"name":"Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan"},{"name":"International Center for Health Information Technology (ICHIT)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Huei","family":"Hsu","sequence":"additional","affiliation":[{"name":"Graduate Institute of Data Science"},{"name":"Research Center of Artificial Intelligence in Medicine and Health (TAIMH), Taipei Medical University, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Moldovan","sequence":"additional","affiliation":[{"name":"South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Yen","sequence":"additional","affiliation":[{"name":"Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan"},{"name":"Ph.D Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University"},{"name":"Taipei Medical University Research Center of Cancer Translational Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chuan (Jack)","family":"Li","sequence":"additional","affiliation":[{"name":"Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan"},{"name":"International Center for Health Information Technology (ICHIT)"},{"name":"Research Center of Artificial Intelligence in Medicine and Health (TAIMH), Taipei Medical University, Taipei, Taiwan"},{"name":"Department of Dermatology, Wan Fang Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Shan","family":"Jian","sequence":"additional","affiliation":[{"name":"School of Health Care Administration, Taipei Medical University, Taipei, Taiwan"},{"name":"Faculty of Health Sciences, Macau University of Science and Technology, Macau"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usman","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Department of Public Health and Community Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Shaikh Zayed Medical Complex, Lahore, Pakistan"},{"name":"International Center for Health Information Technology (ICHIT)"},{"name":"Masters Program in Global Health & Development Department, PhD Program in Global Health and Health Security, College of Public Health, Taipei Medical University, Taipei, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,10]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/joim.12330","article-title":"Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?","volume":"277","author":"Emami-Riedmaier","year":"2015","journal-title":"J Intern Med"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/S0140-6736(14)60886-2","article-title":"The global implications of diabetes and cancer","volume":"383","author":"Shi","year":"2014","journal-title":"Lancet (London, England)"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","article-title":"The influence of glucose-lowering therapies on cancer risk in type 2 diabetes","volume":"52","author":"Currie","year":"2009","journal-title":"Diabetologia"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/ajg.2011.483","article-title":"Use of antidiabetic agents and the risk of pancreatic cancer: a case\u2013control analysis","volume":"107","author":"Bodmer","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/carcin\/bgv077","article-title":"Body size, physical activity, genetic variants in the insulin-like growth factor pathway, and colorectal cancer risk","volume":"36","author":"Simons","year":"2015","journal-title":"Carcinogenesis"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3810\/pgm.2010.05.2153","article-title":"Insulin\u2013carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research","volume":"122","author":"Call","year":"2010","journal-title":"Postgrad Med"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/0284186X.2011.624118","article-title":"Insulin glargine use and short-term incidence of breast cancer - a four-year population-based observation","volume":"51","author":"Ljung","year":"2012","journal-title":"Acta Oncol"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1007\/s00125-011-2190-9","article-title":"Long-term effects of insulin glargine on the risk of breast cancer","volume":"54","author":"Suissa","year":"2011","journal-title":"Diabetologia"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1007\/s00125-009-1418-4","article-title":"Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study","volume":"52","author":"Hemkens","year":"2009","journal-title":"Diabetologia"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.2337\/dc12-1432","article-title":"Prevalence of diagnosed cancer according to duration of diagnosed diabetes and current insulin use among US adults with diagnosed diabetes findings from the 2009 Behavioral Risk Factor Surveillance System","volume":"36","author":"Li","year":"2013","journal-title":"Diabetes Care"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamainternmed.2015.3540","article-title":"Nationwide population science: lessons from the taiwan national health insurance research database","volume":"175","author":"Hsing","year":"2015","journal-title":"JAMA Intern Med"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1377\/hlthaff.22.3.77","article-title":"Does universal health insurance make health care unaffordable? Lessons from Taiwan","volume":"22","author":"Lu J-FR","year":"2003","journal-title":"Health Aff"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1097\/MD.0000000000000483","article-title":"Is long-term use of benzodiazepine a risk for cancer?","volume":"94","author":"Iqbal","year":"2015","journal-title":"Medicine"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/bcp.12001","article-title":"Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study","volume":"75","author":"Potteg\u00e5rd","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","article-title":"Randomized, controlled trials, observational studies, and the hierarchy of research designs","volume":"342","author":"Concato","year":"2000","journal-title":"N Engl J Med"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2337\/dc08-2175","article-title":"New users of metformin are at low risk of incident cancer - a cohort study among people with type 2 diabetes","volume":"32","author":"Libby","year":"2009","journal-title":"Diabetes Care"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","article-title":"The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level","volume":"27","author":"Sahra","year":"2008","journal-title":"Oncogene"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.1158\/0008-5472.CAN-06-4447","article-title":"Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth","volume":"67","author":"Buzzai","year":"2007","journal-title":"Cancer Res"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2337\/dc10-1067","article-title":"Cohort study of pioglitazone and cancer incidence in patients with diabetes","volume":"34","author":"Ferrara","year":"2011","journal-title":"Diabetes Care"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/pds.1352","article-title":"Cancer risks in thiazolidinedione users compared to other anti-diabetic agents","volume":"16","author":"Koro","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1741-7015-5-17","article-title":"Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System","volume":"5","author":"Ramos-Nino","year":"2007","journal-title":"BMC Med"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2337\/dc11-2197","article-title":"Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes - a nationwide, population-based, case-control study","volume":"36","author":"Chen","year":"2013","journal-title":"Diabetes Care"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2337\/dc10-2412","article-title":"Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting","volume":"34","author":"Piccinni","year":"2011","journal-title":"Diabetes Care"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00125-009-1530-5","article-title":"Combined randomised controlled trial experience of malignancies in studies using insulin glargine","volume":"52","author":"Home","year":"2009","journal-title":"Diabetologia"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00125-009-1444-2","article-title":"Insulin glargine use and short-term incidence of malignancies\u2014a population-based follow-up study in Sweden","volume":"52","author":"Jonasson","year":"2009","journal-title":"Diabetologia"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00125-009-1453-1","article-title":"Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group","volume":"52","author":"Colhoun","year":"2009","journal-title":"Diabetologia"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.2337\/db09-1371","article-title":"Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry","volume":"59","author":"Yang","year":"2010","journal-title":"Diabetes"},{"key":"R35-20230915","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1940-6207.CAPR-10-0157","article-title":"Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis","volume":"3","author":"DeCensi","year":"2010","journal-title":"Cancer Prev Res"},{"key":"R36-20230915","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.gastro.2009.04.013","article-title":"Antidiabetic therapies affect risk of pancreatic cancer","volume":"137","author":"Li","year":"2009","journal-title":"Gastroenterology"},{"key":"R37-20230915","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/aje\/kwn190","article-title":"Antidiabetic medication and prostate cancer risk: a population-based case-control study","volume":"168","author":"Murtola","year":"2008","journal-title":"Am J Epidemiol"},{"key":"R38-20230915","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T21:50:56Z","timestamp":1694814656000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":35,"journal-issue":{"issue":"40","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000017461","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}